<DOC>
	<DOCNO>NCT01486446</DOCNO>
	<brief_summary>This Phase 2a single-center , randomize , double-blind , Placebo-controlled , parallel group study XPF-002 applied twice daily 14 21 day patient Primary/Inherited Erythromelalgia ( IEM ) . The purpose study determine whether XPF-002 safe effective treatment pain cause IEM .</brief_summary>
	<brief_title>Phase 2a , Exploratory Study Evaluate Safety , Efficacy , Tolerability Pharmacokinetics XPF-002 Patients With Primary/Inherited Erythromelalgia</brief_title>
	<detailed_description>Your role study would include : - Travelling clinic ( Anniston , Alabama , USA ) 3 out-patient visit , last approximately 1 day - Travelling stay clinic 2 in-patient stay : - For first in-patient visit spend 8 day 7 night clinic - For second in-patient visit spend 2 day 1 night clinic You bring book , laptops DVDs clinic . If live within drive distance clinic need stay local area ( Anniston , local hotel ) 1 2 week use ointment , addition in-patient portion study .</detailed_description>
	<mesh_term>Erythromelalgia</mesh_term>
	<criteria>Must Body Mass Index ( BMI ) 1840 kg/m2 ( inclusive ) Have primary inherit erythromelalgia ( IEM ) Experience flare pain foot hand cause erythromelalgia Be generally healthy ( apart pain ) Stop take usual pain medication certain medication 11.5 week Not pregnant breastfeeding Must able willing provide inform consent willing comply study procedure restriction Must constant pain ( must continually moderate pain , 3/10 ) Coexistent source pain condition may interfere study interpretation HIV , Hepatitis B C Treatment significant depression within 6 month Screening Not willing use adequate contraception Alcoholism , alcohol substance abuse Presence history major psychiatric disturbance Any condition finding may pose undue risk participation Use investigational drug 30 day prior dose Donation loss whole blood plasma prior dose follow : 50 mL 499 mL within 30 day , 499 mL within 56 day Employee relative employee directly involve study</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>IEM</keyword>
	<keyword>EM</keyword>
	<keyword>Erythromelalgia</keyword>
	<keyword>Erythermalgia</keyword>
	<keyword>Red neuralgia</keyword>
	<keyword>Peripheral Vascular Disease</keyword>
	<keyword>Vascular Disease</keyword>
	<keyword>Cardiovascular Disease</keyword>
</DOC>